AnimalhealthEurope is pleased to have had the opportunity to actively collaborate with the authorities in submitting detailed input to the ongoing consultation on the EU-wide restriction of per- and polyfluoroalkyl substances (PFAS). As part of this process, we have provided key data on the animal health sector, previously identified by the Committee for Socio‑Economic Analysis (SEAC) of the European Chemicals Agency (ECHA) as missing, reinforcing our commitment to transparency and evidence‑based regulation.

As stated this week by global and European ministers during the World Organisation for Animal Health General Session, animal health (and by extension, veterinary medicines) play an essential role in food and nutrition security, economic stability, safe trade, poverty reduction, and in preventing health crises at the human–animal–environment interface. Building on this impetus for greater global political recognition of the value of animal health, we count on EU authorities to recognise the wide‑ranging benefits of veterinary medicines.

The animal health industry understands and shares public concern about the potential human health and environmental impacts of certain PFAS. While we acknowledge that EU‑wide action is needed and welcome this opportunity to contribute to the socio-economic evaluation, it must be understood that the sector relies on APIs that may be classified as PFAS, as well as other PFAS and fluoropolymer‑containing materials, such as gaskets, stoppers, filters and selected packaging materials, required for the safe manufacturing, distribution and use of veterinary medicines, including vaccines.

Roxane Feller, AnimalhealthEurope Director General commented:
“Although the veterinary medicines sector has limited use of PFAS, such use fulfils essential therapeutic needs required by Europe’s 300,000 veterinarians, over 3 million farms with livestock, and 139 million pet-owning households. During this consultation phase and beyond, we look forward to working closely with ECHA and the European Commission on appropriate derogations for uses where no alternatives currently exist, and on the implementation of measures that contain emissions.

Our member companies continue to invest in research to identify viable substitutions where and when possible. Restriction decisions should therefore be based on the availability of alternatives and in a clear understanding of socio‑economic impacts. The ultimate goal must be to manage PFAS responsibly while safeguarding the health and welfare of Europe’s companion animals and livestock, and ensuring the safety and affordability of our food supply.”